Liquidia Technologies (LQDA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Pulmonarysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 14/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 20.31% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
- Why Liquidia (LQDA) Is Up 24.1% After Striking Costly Peace Deal On YUTREPIA Litigation
- How Much Downside Is Left In Liquidia Stock?
- What to Know as Liquidia, United Therapeutics Settlement Sends LQDA Stock Soaring
- Sector Update: Healthcare Stocks Gain Late Afternoon
- LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Liquidia Technologies.
Full LQDA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.